Development of an individualized drug-‐screening tool for guiding therapy selection in glioblastoma patients (2)
Bijdrage Stichting STOPhersentumoren.nl: 35.000,- euro per 6 december 2019
The IMAGIT project (Individualized Models for Astrocytic Glioma Immune Therapy)
Bijdrage Stichting STOPhersentumoren.nl: 90.000,- euro per 4 november 2019
RNE SEQ in the CATNON trial bij glioompatienten
Bijdrage Stichting STOPhersentumoren.nl: 80.000,- euro per 4 november 2019
IBTA to advocate for the best treatments, information, support and quality of life for brain tumour patients
Bijdrage Stichting STOPhersentumoren.nl: 125.000,- euro per 4 november 2019
Non-invasie predictive GBM
Bijdrage Stichting STOPhersentumoren.nl: 18.500,- euro per 4 november 2019
